Turbine and Daiichi Sankyo Expand ADC Discovery Collaboration
Read more

A Lab Without Limits

Explore every hypothesis without being constrained by time, cost, or experimental capacity.
Learn more

KEY BENEFITS

∞

hypotheses
predicted in hours

Design studies using 1400+ of virtual samples with hundreds of therapeutic agents and combinations.
3-5x

faster time to decisions

Surface meaningful biological signals earlier than traditional methods using shared workflows, toolkits, and visualizations.
50%

fewer wet lab experiments

Evaluate millions of possibilities in silico to find the ideas most likely to succeed.
50%

higher likelihood of validation

Improve translatability with mechanistic understanding of biological response.

TURBINE IN ACTION

Millions of in silico experiments are run so that selected
wet lab experiments have the highest probability of success

A Complete Platform For Biopharma Discovery

VIRTUAL LAB

Explore hypotheses at a scale no traditional lab can achieve by running virtual experiments.
Learn more

LAB IN THE LOOP

Validate the most promising hypotheses identified in silico to sharpen the shortlist and increase probability of success.
Learn more
Discovery

Identify & derisk new targets

Explore therapeutic areas, target discovery and de-risk programs, and prioritize experiments based on mechanism, biomarkers, and clinical potential.
Translational

Predict in silico to boost translatability across biological contexts

Interpret simulations on patient-relevant disease profiles to determine drivers of clinical response.

FEATURED PUBLICATIONS

Turbine has provided multiple targets that have first-in-class potential, along with the biology-driven insights necessary to rapidly validate this potential.
— Seishi Katsumata
Corporate Officer, Executive Director of Discovery & Research at Ono Pharmaceutical
We believe Turbine’s Simulated Cell has the potential to transform key aspects of the oncology drug discovery and development process, providing insight at scale that will shed light on even the most challenging biological mechanisms.
— David M. Rubin
Managing Director at MSD Global Health Fund
Turbine's AI-based platform has clearly demonstrated the ability to unlock high-quality biological insights for our clients across the biopharma industry.
— Tom Lounibos
Global Managing Director of Accenture Ventures
Turbine can fundamentally change the way in which novel targets in precision oncology are identified.
— Alan Barge
ex VP and Head of Oncology and Infection at AstraZeneca
Discover how the vLab® helps accelerate and de-risk your research & discovery programs.
Book a demo